Condensed Memorial Symptom Assessment Scale (CMSAS)

1. Abstract

The Condensed Memorial Symptom Assessment Scale (CMSAS) is a validated, multidimensional patient-reported outcome measure (PROM) developed to capture symptom burden rapidly and accurately in clinical oncology, palliative medicine, and chronic disease epidemiology. Derived from the original 32-item Memorial Symptom Assessment Scale (MSAS) and its Short Form (MSAS-SF), the CMSAS distills symptom evaluation down to a core battery of 14 prevalent and clinically impactful symptoms. The instrument incorporates two psychometrically distinct dimensions: a 10-item Physical Symptom Subscale (CMSAS-PHYS) assessing physical symptom-associated distress, and a 4-item Psychological Symptom Subscale (CMSAS-PSYCH) measuring psychological symptom frequency. A global summary metric, the CMSAS Total Score, reflects overall symptom burden. Physical symptoms (such as lack of energy, pain, dry mouth, weight loss, feeling drowsy, constipation, numbness/tingling in hands/feet, shortness of breath, nausea, and vomiting) are evaluated on a conditioned 5-point distress continuum ranging from 0 (“Did not have symptom”) to 5 (“Very much”), or scored using proportionate weighting (0, 0.8, 1.6, 2.4, 3.2, 4.0) to maintain congruence with parent instruments. Psychological symptoms (feeling sad, worrying, feeling irritable, and feeling nervous) are evaluated using a 4-point temporal frequency scale ranging from 1 (“Rarely”) to 4 (“Almost constantly”), with absence scored as 0. Extensively evaluated across diverse advanced cancer cohorts, the CMSAS demonstrates robust internal consistency reliability (Cronbach’s alpha coefficients typically ranging between 0.75 and 0.88), strong criterion and construct validity through convergent correlations with functional status performance scales such as the Karnofsky Performance Scale (KPS) and the Functional Assessment of Cancer Therapy (FACT), and exemplary clinical utility by significantly reducing respondent burden in medically compromised, frail populations.

2. Keywords

Condensed Memorial Symptom Assessment Scale, CMSAS, symptom burden, oncology psychometrics, palliative care assessment, patient-reported outcome measures, physical symptom distress, psychological symptom frequency, cancer-related distress, quality of life

3. Authors

The Condensed Memorial Symptom Assessment Scale was developed and validated by a multidisciplinary team of medical oncologists, palliative care specialists, and biostatisticians:

• Victor T. Chang, MD — Hematology/Oncology Section, Department of Veterans Affairs New Jersey Health Care System, East Orange, NJ; and Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, United States.
• Sorah S. Hwang, MD — Department of Veterans Affairs New Jersey Health Care System, East Orange, NJ, United States.
• Basil Kasimis, MD, FACP — Division of Hematology/Oncology, Department of Veterans Affairs New Jersey Health Care System, East Orange, NJ; and Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, United States.
• Howard T. Thaler, PhD — Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

4. Purpose

The primary purpose of the Condensed Memorial Symptom Assessment Scale (CMSAS) is to provide clinicians, clinical trialists, and health services researchers with an ultra-efficient, psychometrically rigorous instrument designed to evaluate multidimensional symptom burden in patients facing serious, life-limiting illnesses. Patients undergoing intensive antineoplastic therapies or receiving supportive and palliative end-of-life care often experience high levels of concurrent physical and psychological distress. While comprehensive symptom inventories provide granular clinical insight, their administration frequently imposes an untenable cognitive and physical burden on frail, fatigued, or cognitively compromised individuals. The CMSAS resolves this clinical-measurement paradox by reducing the 32 items of the original Memorial Symptom Assessment Scale down to the 14 most pervasive, discriminative, and distressing symptoms encountered across solid tumor and hematologic malignancies.

From a clinical perspective, the CMSAS functions as a rapid triaging mechanism. Because physical symptoms are assessed via patient distress while psychological symptoms are assessed via temporal frequency, the instrument captures distinct phenomenological expressions of illness. This differentiation prevents clinical oversight; for example, an oncology patient might experience high physical distress from nausea or pain requiring acute pharmacologic intervention, alongside severe existential anxiety or pervasive sadness requiring immediate psychosocial or psychiatric consultation. The subscales allow clinical teams to monitor therapeutic response over time, track adverse reactions to cytotoxic chemotherapy or targeted immunotherapy, and calibrate palliative interventions.

In clinical trials and comparative effectiveness research, the CMSAS addresses high rates of missing data that routinely compromise longitudinal quality-of-life studies. When questionnaires are excessively long, severely ill patients drop out or skip items non-randomly, introducing systematic attrition bias. By significantly attenuating completion time to approximately two to three minutes, the CMSAS preserves data integrity and trial retention while retaining substantial empirical overlap with parent instruments. Consequently, the scale is indicated for inpatient oncology services, outpatient infusion suites, radiation oncology clinics, hospice programs, and longitudinal health-related quality of life (HRQoL) research.

5. Psychological Construct

The CMSAS evaluates symptom burden, an integrative, multidimensional clinical construct that reflects the cumulative physical, affective, and cognitive toll imposed by disease progression and therapeutic toxicity. Rather than treating symptoms as isolated biometric indicators, the construct operationalized by the CMSAS posits that illness perception involves both physiological disruptions and subjective emotional distress. In accordance with the foundational architecture of the Memorial Symptom Assessment Scale lineage, symptom burden in the CMSAS is conceptualized along two primary dimensions: physical symptom distress and psychological symptom frequency.

Physical Symptom Distress (CMSAS-PHYS)

The CMSAS-PHYS domain encompasses 10 prevalent physical symptoms: lack of energy, pain, dry mouth, weight loss, feeling drowsy, constipation, numbness/tingling in hands/feet, shortness of breath, nausea, and vomiting. Methodologically, the scale distinguishes between the objective presence of a physical perturbation and the subjective distress (bother, emotional suffering, or functional disruption) it causes the individual. This construct recognizes that identical physiological states can evoke disparate subjective suffering based on patient coping mechanisms, psychological resilience, and somatic meaning.

For example, a patient with chemotherapy-induced peripheral neuropathy may report mild numbness, yet find it extraordinarily distressing due to its interference with ambulation or manual dexterity. Conversely, profound fatigue may be accepted stoically by another patient, resulting in minimal reported distress. By measuring the distress continuum (from “Not at all” to “Very much”), the CMSAS-PHYS construct isolates clinically actionable suffering that warrants medical palliation.

Psychological Symptom Frequency (CMSAS-PSYCH)

The CMSAS-PSYCH domain encompasses 4 psychological symptoms: feeling sad, worrying, feeling irritable, and feeling nervous. In contrast to physical symptoms, psychological symptoms are operationalized via temporal frequency (ranging from “Rarely” to “Almost constantly”). Psychometrically, empirical findings from the parent MSAS demonstrated that psychological suffering is more reliably indexed by its chronicity and intrusion into daily conscious experience than by isolated ratings of distress or intensity.

A patient experiencing persistent, pervasive rumination and nervous tension (“Almost constantly”) exhibits a state indicative of clinically significant affective pathology, such as major depressive disorder or generalized anxiety disorder. By focusing on frequency, the CMSAS-PSYCH isolates sustained cognitive and emotional dysregulation from transient, normative situational responses to medical visits or procedural anxieties.

Global Symptom Burden (CMSAS Total Score)

The composite CMSAS Total Score represents an overarching index of systemic symptom burden. In psychometric terms, this composite functions as a formative or higher-order construct wherein the synergistic combination of physical distress and affective disruption reflects the total biobehavioral impact of illness. It reflects the understanding that physical distress exacerbates affective vulnerability, and heightened psychological distress lowers physical symptom thresholds, generating a reinforcing cycle of systemic morbidity.

6. Theoretical Framework

The theoretical architecture of the CMSAS is grounded in the Biopsychosocial Model of Medicine articulated by George Engel, the Theory of Symptom Management (TSM) developed by Larson, Dodd, and colleagues, and cognitive appraisal theories of stress and coping formulated by Richard Lazarus and Susan Folkman.

The Biopsychosocial Model

Engel’s biopsychosocial framework rejected biomedical reductionism, asserting that clinical outcomes cannot be disentangled from the psychological and social contexts of the patient. In cancer and chronic somatic illness, tumor biology and pharmacologic toxicities represent only the biological substrate. The CMSAS translates this theoretical premise into measurement practice by evaluating affective states (sadness, worry, irritability, nervousness) alongside somatic manifestations (pain, nausea, dyspnea), formally operationalizing the principle that mental and physical suffering are mutually constitutive components of human pathology.

The Theory of Symptom Management

The Theory of Symptom Management provides a dedicated nursing and palliative framework comprising three interacting domains: the symptom experience, symptom management strategies, and symptom outcomes. The CMSAS focuses explicitly on the symptom experience, which consists of an individual’s perception of a symptom, evaluation of its meaning, and behavioral or emotional response to it. By parsing symptoms into physical distress and psychological frequency, the CMSAS honors the TSM proposition that symptoms are multidimensional experiences requiring separate characterization of sensory, evaluative, and affective dimensions.

Cognitive Appraisal and Phenomenological Distress

Lazarus and Folkman’s transactional model posits that distress is the outcome of a cognitive appraisal process wherein an environmental demand (such as a bodily alteration) is perceived as exceeding the individual’s coping resources. In the CMSAS, physical symptoms are explicitly assessed via appraisal of “bother or distress.” A symptom does not produce distress automatically; rather, the patient cognitively appraises the symptom in relation to functional autonomy, threat to survival, and personal discomfort. By anchoring the physical scale to distress, the CMSAS directly operationalizes cognitive appraisal theory, quantifying the psychological impact of somatic disease.

7. Validity

The validity of the CMSAS has been demonstrated across diverse oncology populations, with primary empirical validation established in the landmark study by Chang, Hwang, Kasimis, and Thaler (2004). Validation studies have addressed construct validity, criterion-related validity, convergent validity, and discriminant validity.

Construct and Convergent Validity

Construct validity was established by comparing the CMSAS against its parent instruments, the MSAS and the MSAS-SF, as well as established functional and quality-of-life benchmarks. In the primary validation study involving cancer inpatients and outpatients, the correlation between the CMSAS Physical Symptom Subscale and the original MSAS Physical Subscale exceeded $r = 0.90$, demonstrating near-perfect preservation of construct capture despite substantial item reduction. Similarly, the CMSAS Psychological Symptom Subscale correlated strongly ($r > 0.85$) with the parent MSAS Psychological Subscale and with the Global Distress Index (GDI).

Convergent validity has been repeatedly corroborated through significant correlations with external clinical scales. The CMSAS Total Score correlates inversely with the Karnofsky Performance Scale (KPS; $r = -0.45$ to $-0.55$, $p < 0.001$), indicating that declining functional performance is systematically accompanied by escalating symptom burden. Furthermore, moderate-to-high correlations have been documented with the Functional Assessment of Cancer Therapy-General (FACT-G) total score ($r = -0.60$ to $-0.70$) and its physical and emotional well-being subscales, confirming that higher CMSAS scores reflect diminished quality of life.

Discriminant and Known-Groups Validity

Known-groups validity was confirmed by the instrument’s capacity to differentiate between distinct clinical subpopulations defined by disease extent and treatment status. Patients with advanced metastatic cancer exhibited statistically significantly higher CMSAS Total and CMSAS-PHYS scores than patients with localized disease ($p < 0.01$). Inpatients, who typically harbor higher acute disease acuity, scored significantly higher across both physical distress and psychological frequency subscales compared to stable outpatients. In addition, the CMSAS demonstrates discriminant validity when evaluated alongside distinct constructs; its correlation with non-somatic constructs, such as social well-being, is weak to negligible ($r < 0.25$), confirming that the tool specifically isolates symptom burden rather than generalized negative affect or existential dissatisfaction.

8. Reliability

The Condensed Memorial Symptom Assessment Scale possesses high psychometric reliability, demonstrated through internal consistency and temporal stability metrics across multiple clinical trials and observational cohorts.

Internal Consistency

Internal consistency reliability, assessed via Cronbach’s alpha ($lpha$), consistently meets or exceeds rigorous psychometric standards for both clinical screening and research applications:

• CMSAS Total Score: Cronbach’s alpha values across oncology cohorts typically range between 0.82 and 0.88, indicating excellent overall reliability for a 14-item brief measure.
• CMSAS-PHYS (Physical Subscale): Cronbach’s alpha values range from 0.75 to 0.83 across 10 items. This is remarkably robust given the heterogeneous nature of somatic complaints (e.g., nausea vs. numbness), where high inter-item correlations are naturally constrained by diverse biological etiologies.
• CMSAS-PSYCH (Psychological Subscale): Despite comprising only 4 items, the psychological subscale demonstrates high internal consistency, with alpha coefficients consistently spanning 0.76 to 0.84.

Test-Retest Reliability and Temporal Stability

Evaluating test-retest reliability in advanced illness populations presents inherent methodological challenges due to rapid fluctuations in acute symptom trajectories, analgesic titrations, and antineoplastic interventions. However, among clinically stable oncology cohorts reassessed within a 24- to 48-hour window, intra-class correlation coefficients (ICCs) for the CMSAS Total Score ranged from 0.80 to 0.87, and subscale ICCs ranged from 0.74 to 0.82. These findings confirm that the CMSAS captures stable symptom dispositions while retaining sensitivity to acute therapeutic shifts.

9. Factor Analysis

The structural dimensionality of the CMSAS was rigorously evaluated during its initial derivative validation using exploratory factor analysis (EFA) and subsequent confirmatory factor analysis (CFA).

Exploratory Factor Analysis

Principal axis factoring with oblique (promax/oblimin) rotation on the 14 items consistently reveals a distinct two-factor solution, mirroring the theoretical bifurcation of physical distress and psychological frequency:

• Factor 1: Physical Symptom Distress. Items evaluating lack of energy, pain, dry mouth, weight loss, drowsiness, constipation, numbness/tingling, shortness of breath, nausea, and vomiting load strongly on this factor (factor loadings ranging from 0.42 to 0.78). Cross-loadings onto the psychological dimension remain low (< 0.25).
• Factor 2: Psychological Symptom Frequency. Items assessing feeling sad, worrying, feeling irritable, and feeling nervous demonstrate high, distinct factor loadings (ranging from 0.65 to 0.86) onto this second dimension.

Confirmatory Factor Analysis and Model Fit

Subsequent confirmatory factor analyses examining the 2-factor latent structure have demonstrated acceptable to good model fit indices in oncology populations:

• Comparative Fit Index (CFI): Values typically range between 0.92 and 0.96, exceeding standard adequacy thresholds.
• Tucker-Lewis Index (TLI): Coefficients regularly fall between 0.90 and 0.95.
• Root Mean Square Error of Approximation (RMSEA): Estimates range from 0.048 to 0.068 (with 90% confidence intervals well within the acceptable psychometric boundary of < 0.08).
• Standardized Root Mean Square Residual (SRMR): Observed values are generally below 0.055.

While a single-factor unidimensional model demonstrates poor statistical fit, a higher-order hierarchical model—wherein a superordinate “Global Symptom Burden” factor accounts for the shared covariance between the physical and psychological latent dimensions—yields strong goodness-of-fit parameters, validating both subscale reporting and composite total scoring.

10. Instrument / Measurement Tool

The Condensed Memorial Symptom Assessment Scale is a patient-reported outcome measure designed for self-administration, but it can also be administered via structured clinical interview for patients with severe fatigue, visual impairment, or motor deficits.

• Test Type: Multi-item, multidimensional patient-reported outcome rating scale.
• Administration Format: Paper-and-pencil questionnaire, digital survey (tablet/smartphone interface), or structured clinician-assisted interview.
• Target Population: Adult oncology patients (solid tumors and hematologic malignancies), individuals in palliative and hospice care, and patients with advanced chronic medical illnesses.
• Completion Time: Approximately 2 to 3 minutes.
• Recall Period: Past 7 days (the previous week).
• Item Count: 14 items total (10 physical symptoms and 4 psychological symptoms).
• Authentic Response Scale:
  • Physical symptoms (Items 1-10): Rated for distress on a 5-point scale: 0 = Did not have symptom, 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, 5 = Very much (or 0-4 distress scale if symptom present). In standard MSAS proportionate scoring, presence weights are calibrated as: 0 = Did not have symptom, 0.8 = Not at all, 1.6 = A little bit, 2.4 = Somewhat, 3.2 = Quite a bit, 4.0 = Very much.
  • Psychological symptoms (Items 11-14): Rated for frequency on a 4-point scale: 1 = Rarely, 2 = Occasionally, 3 = Frequently, 4 = Almost constantly (0 = Did not have symptom).
• Subscales and Scoring Rules:
  • CMSAS Physical Symptom Subscale (CMSAS-PHYS): The average score of the 10 physical symptom distress items (Items 1 through 10). If a symptom is not present, it is scored 0. Total sum divided by 10.
  • CMSAS Psychological Symptom Subscale (CMSAS-PSYCH): The average score of the 4 psychological symptom frequency items (Items 11 through 14). If a symptom is not present, it is scored 0. Total sum divided by 4.
  • CMSAS Total Score: Calculated as the arithmetic mean across all 14 symptom scores (sum of all 14 items divided by 14).

11. Permissions & Fee and Test Year

The Condensed Memorial Symptom Assessment Scale was developed and published in 2004 by Dr. Victor T. Chang and colleagues. It is in the public domain for non-commercial academic, clinical, and non-funded research purposes. Healthcare systems, palliative units, and non-profit academic institutions may utilize and integrate the CMSAS into clinical practice or electronic health records (EHR) without royalty fees or formal licensing charges, provided appropriate citation and attribution are given to the original authors and validation publication (Chang et al., 2004).

Commercial entities, pharmaceutical corporations, or sponsored clinical trial management organizations seeking to incorporate the scale into commercial clinical trials, proprietary electronic platforms, or profit-driven software products should contact the primary developer (Dr. Victor T. Chang, Department of Veterans Affairs New Jersey Health Care System, East Orange, NJ) or the copyright holder of the parent instruments at Memorial Sloan Kettering Cancer Center, New York, NY, for licensing verification and express authorization.

12. References

Chang, V. T., Hwang, S. S., Kasimis, B., & Thaler, H. T. (2004). Shorter symptom assessment instruments: The Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Investigation, 22(4), 526–536. https://doi.org/10.1081/cnv-120034403

Chang, V. T., Hwang, S. S., Feuerman, M., Kasimis, B., & Thaler, H. T. (2000). The Memorial Symptom Assessment Scale Short Form (MSAS-SF): Validity and reliability. Cancer, 89(5), 1162–1171. https://doi.org/10.1002/1097-0142(20000901)89:5<1162::AID-CNCR26>3.0.CO;2-C

Dodd, M., Janson, S., Facione, N., Faucett, J., Froelicher, E. S., Humphreys, J., Lee, K., Miaskowski, C., Puntillo, K., Rankin, S., & Taylor, D. (2001). Advancing the science of symptom management. Journal of Advanced Nursing, 33(5), 668–676. https://doi.org/10.1046/j.1365-2648.2001.01697.x

Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460

Lazarus, R. S., & Folkman, S. (1984). Stress, appraisal, and coping. Springer Publishing Company.

Portenoy, R. K., Thaler, H. T., Kornblith, A. B., Lepore, J. M., Friedlander-Klar, H., Kiyasu, E., Sobel, K., Coyle, N., Kemeny, N., Norton, L., & Scher, H. (1994). The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress. European Journal of Cancer, 30(9), 1326–1336. https://doi.org/10.1016/0959-8049(94)90182-4

13. Items of the Scale